A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer

[1]  C. Boni,et al.  51A Docetaxel (D), cisplatin (C) 5-fluorouracil (F) compared to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a randomized phase III trial (V325) , 2003 .

[2]  D. Miles,et al.  XELODA® AND TAXOTERE®: A REVIEW OF THE DEVELOPMENT OF THE COMBINATION FOR USE IN METASTATIC BREAST CANCER , 2003, International journal of clinical practice.

[3]  T. Taguchi,et al.  A Pilot Phase II Study of Capecitabine in Advanced or Recurrent Gastric Cancer , 2003, Oncology.

[4]  B. Dörken,et al.  Recurrent Gastric Adenocarcinoma with Unusual Metastatic Localization and Excellent Responseto Docetaxel and 5-FU Continuous Infusion , 2003, Oncology Research and Treatment.

[5]  R. Garcia-Arroyo,et al.  Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study , 2002, Gastric Cancer.

[6]  Y. Bang,et al.  Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. , 2002, Japanese journal of clinical oncology.

[7]  David Miles,et al.  Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  E. Cho,et al.  Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for advanced gastric carcinoma. , 2002, Journal of Korean medical science.

[9]  D. Haller,et al.  Docetaxel in advanced gastric cancer , 2002, Anti-cancer drugs.

[10]  R. Schilsky,et al.  First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  C. Twelves.  Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. , 2002, European journal of cancer.

[12]  E. Van Cutsem,et al.  Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Y. Mok,et al.  Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma , 2001, Cancer.

[14]  E Harrison,et al.  Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  L. Crinò,et al.  The gemcitabine/epirubicin/paclitaxel trials in advanced breast cancer. , 2001, Oncology.

[16]  B. Reigner,et al.  A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours , 2000, British Journal of Cancer.

[17]  R. Kanamaru,et al.  [A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B)]. , 1999, Gan to kagaku ryoho. Cancer & chemotherapy.

[18]  R. Kanamaru,et al.  [Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A)]. , 1998, Gan to kagaku ryoho. Cancer & chemotherapy.

[19]  H. Ishitsuka,et al.  Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. , 1998, European journal of cancer.

[20]  H. Ishitsuka,et al.  Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  Eui-Pyeong Lee.  Analysis on the Actual Conditions of Deaths due to Fires based on Annual Report on the cause of Death Statistics in Korea , 2006 .

[22]  J. Yook,et al.  Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  H. Lippert,et al.  Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  B. Reigner,et al.  Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients , 2000, Cancer Chemotherapy and Pharmacology.

[25]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[26]  D. Neuberg,et al.  Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) Results of Protocol E1293 , 1996, Medical oncology.